WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001032157) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND GLIBENCLAMIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/032157    International Application No.:    PCT/US2000/028311
Publication Date: 10.05.2001 International Filing Date: 13.10.2000
Chapter 2 Demand Filed:    27.04.2001    
IPC:
A61K 31/155 (2006.01), A61K 31/64 (2006.01), A61K 45/06 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000 Princetown, NJ 08543-4000 (US) (For All Designated States Except US).
PIPER, Beth, Anne [US/US]; (US) (For US Only)
Inventors: PIPER, Beth, Anne; (US)
Agent: ALGIERI, Aldo, A.; Bristol-Myers Squibb Company P.O. Box 4000 Princeton, NJ 08543-4000 (US)
Priority Data:
09/432,465 03.11.1999 US
09/460,920 14.12.1999 US
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND GLIBENCLAMIDE
(FR) PROCEDE UTILISE POUR TRAITER LE DIABETE
Abstract: front page image
(EN)A method is provided for first line treatment of type 2 diabetes employing a combination of metformin and glyburide. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or hemoglobin 1Ac, and/or increase post-prandial insulin, thereby treating the diabetes.
(FR)L'invention concerne un procédé de traitement de premier niveau du diabète de type 2. Ce procédé consiste à utiliser une combinaison de metformine et de glybenclamide. L'invention concerne également un procédé de traitement du diabète chez des patients humains naïfs en employant la formulation susmentionnée, afin de réduire la résistance à l'insuline et/ou l'excursion de glucose post-prandial et/ou d'hémoglobine 1Ac, et/ou augmenter l'insuline post-prandiale, traitant ainsi le diabète.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)